[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336352-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336352-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cea-ceacam5-expression-is-common-in-muscle-invasive-urothelial-carcinoma-of-the-bladder-but-unrelated-to-the-disease-course","CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course","","This study assesses the clinical significance of carcinoembryonic antigen (CEA; CEACAM5) expression in urothelial bladder neoplasms. CEA was examined by immunohistochemistry in a tissue microarray containing over 2500 urothelial bladder carcinomas. CEA staining was largely absent in normal urothelium but present in 30.4% of carcinomas, with positivity increasing by tumor grade. In pT2–4 carcinomas, CEA positivity was not associated with pT, pN, grade, or survival outcomes, yet supports CEA serum monitoring and anti-CEA targeted drug candidacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cea-ceacam5-expression-is-common-in-muscle-invasive-urothelial-carcinoma-of-the-bladder-but-unrelated-to-the-disease-course/336352/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cea-ceacam5-expression-is-common-in-muscle-invasive-urothelial-carcinoma-of-the-bladder-but-unrelated-to-the-disease-course/336352.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of measuring CEA (CEACAM5) in urothelial bladder cancer?","Question",{"text":63,"@type":64},"The study aims to evaluate the potential clinical significance of CEA expression and the possibility of using serum CEA monitoring. It also considers CEA-positive tumors as candidates for targeted anti-CEA treatment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was CEA expression assessed in the study?",{"text":68,"@type":64},"CEA was analyzed by immunohistochemistry on a tissue microarray containing more than 2500 urothelial bladder carcinomas.",{"name":70,"@type":61,"acceptedAnswer":71},"What relationship does CEA have with tumor grade and cancer course?",{"text":72,"@type":64},"CEA expression increases markedly with grade progression in pTa tumors and occurs in a significant fraction of pT2–4 carcinomas. Within pT2–4 carcinomas, CEA positivity was unrelated to pT, pN, grade, and several survival and recurrence outcomes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336352,1790140310,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","DOI: 10.1002/bco2.354  \nORIGINA L ARTICLE  \nCEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course  \nHenning Plage 1 | Kira Furlano 1 | Jörg Neymeyer 1 | Sarah Weinberger 1 | Benedikt Gerdes 1 | Mandy Hubatsch 1 | Bernhard Ralla 1 | Antonia Franz 1 | Annika Fendler 1 | Michela de Martino 1 | Florian Roßner 2 | Simon Schallenberg 2 | Sefer Elezkurtaj 2 | Martina Kluth 3 | Maximilian Lennartz 3 | Niclas C. Blessin 3 | Andreas H. Marx 4 | Henrik Samtleben 4 | Margit Fisch 5 | Michael Rink 6 | Krystian Kaczmarek 7 | Thorsten Ecke 8 | Steffen Hallmann 8 | Stefan Koch 9 | Nico Adamini 10 | Sarah Minner 3 | Ronald Simon 3  | Guido Sauter 3 |  \nJoachim Weischenfeldt 1,11,12 | Tobias Klatte 8 | Thorsten Schlomm 1 | David Horst 2 | Henrik Zecha 1,10 | Marcin Slojewski 7  \n1Department of Urology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany  \n2Institute of Pathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany  \n3Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 4Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany  \n5Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 6Department of Urology, Marienhospital Hamburg, Hamburg, Germany  \n7Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland 8Department of Urology, Helios Hospital Bad Saarow, Bad Saarow, Germany  \n9Department of Pathology, Helios Hospital Bad Saarow, Bad Saarow, Germany 10Department of Urology, Albertinen Hospital, Hamburg, Germany  \n11Biotech Research & Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark 12Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark  \nCorrespondence  \nRonald Simon, Institute of Pathology, University Medical Center HamburgEppendorf, Martinistr. 52, 20246 Hamburg, Germany.  \nEmail: [r.simon@uke.de](r.simon@uke.de)  \nFunding information No funding.  \nAbstract  \nObjectives: Carcinoembryonic antigen (CEA) is a cell surface glycoprotein that represents a promising therapeutic target. Serum measurement of shedded CEA can be utilized for monitoring of cancer patients.  \nMaterial and Methods: To evaluate the potential clinical significance of CEA expression in urothelial bladder neoplasms, CEA was analysed by immunohistochemistry in more than 2500 urothelial bladder carcinomas in a tissue microarray format.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.  \nResults: CEA staining was largely absent in normal urothelial cells but was observed in 30.4% of urothelial bladder carcinomas including 406 (16.7%) with weak, 140 (5 .8%) with moderate, and 192 (7 .9%) with strong staining. CEA positivity occurred in 10.9% of 411 pTaG2 low-grade, 32.0% of 178 pTaG2 high-grade, and 43.0% of 93 pTaG3 tumours (p \u003C 0 .0001) . In 1335 pT2–4 carcinomas, CEA positivity (34 . 1%) was lower than in pTaG3 tumours. Within pT2–4 carcinomas, CEA staining was unrelated to pT, pN, grade, L-status, V-status, overall survival, recurrence free survival, and cancer specific survival ( p > 0 .25) .  \nConclusion: CEA increases markedly with grade progression in pTa tumours, and expression occurs in a significant fraction of pT2–4 urothelial bladder carcinomas. The high rate of CEA positivity in pT2–4 carcinomas offers the opportunity of using CEA serum measurement for monitoring the clinical course of these cancers. Moreover, CEA positive urothelial carcinomas are candidates for a tre","cbCaijBMDqbQ734F","https://ap.wps.com/l/cbCaijBMDqbQ734F","pdf",832989,"English","# Objectives\n# Material and Methods\n# Results\n## CEA staining distribution\n## Association with staging and survival\n# Conclusion","[{\"question\":\"What is the purpose of measuring CEA (CEACAM5) in urothelial bladder cancer?\",\"answer\":\"The study aims to evaluate the potential clinical significance of CEA expression and the possibility of using serum CEA monitoring. It also considers CEA-positive tumors as candidates for targeted anti-CEA treatment.\"},{\"question\":\"How was CEA expression assessed in the study?\",\"answer\":\"CEA was analyzed by immunohistochemistry on a tissue microarray containing more than 2500 urothelial bladder carcinomas.\"},{\"question\":\"What relationship does CEA have with tumor grade and cancer course?\",\"answer\":\"CEA expression increases markedly with grade progression in pTa tumors and occurs in a significant fraction of pT2–4 carcinomas. Within pT2–4 carcinomas, CEA positivity was unrelated to pT, pN, grade, and several survival and recurrence outcomes.\"}]","CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course | PDF",1790014681,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6113b1dfba03f6f9ed8a3f35f30f860.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d83fe519bc0fb08f7ac1adf1cac1687.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3491ca3417f212315d00c173a60651e6.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69ae53f37d9a7adb91a53884cfa6972f.webp",980,1287]